Patent application EP16001501A (EP), filed 2016-07-06
Publication number: EP3251662A1
Title: MATRIX-EMBEDDED TOLERANCE-PROMOTION ADJUVANTS FOR SUBCUTANEOUS IMMUNOTHERAPY
Abstract: The present invention relates to compositions and methods for the application of tolerance-promoting adjuvants embedded in alum-, microcrystalline tyrosine-, or hydrogel-based formulations for allergen- or autoantigen-specific immunotherapy.
IPC codes: A61K  38/    17            A I
A61K  39/    00            A I
A61K   9/    51            A I
A61P  37/    06            A I
A61P  37/    08            A I
Claims: number: 1
text: Pharmaceutical composition for subcutaneous allergen- or autoantigen-specific immunotherapy of allergic and autoimmune diseases using matrix-based compositions for subcutaneous administration comprising matrix-embedded allergens or autoantigens or fragments thereof, one or more tolerance-promoting adjuvants, optionally one or more low molecular weight find-me molecules, and optionally one or more tolerance-promoting immune modulators suitable for enhancing the suppressive function of regulatory T cells and/or inhibiting the production of pro-inflammatory cytokines, and/or inhibiting the biological activity of secreted pro-inflammatory cytokines at the site of antigen or allergen presentation.
number: 2
text: Composition of claim 1, wherein the matrix suitable for locally restricted sustained release of embedded therapeutics is selected from alum-, micro crystalline tyrosine-; or hydrogel-based formulations, wherein preferred hydrogel-based matrices are selected from the group consisting of polyethylene, polypropylene, polyethylene oxide (PEO), polypropylene oxide (PPO), polyurethane, polyurea, polyamides, polycarbonates, polyaldehydes, polyorthoesters, polyiminocarbonates, poly caprolactone (PCL), poly-D,L-lactic acid (PDLLA), poly-L-lactic acid (PLLA), lactides of said lactic acids, polyphosphazenes, polyglycolic acids, albumin, monomethoxypoly(ethylene glycol) (MPEG), trimethylated chitosan derivatives, or copolymers or mixtures of any of the above including poly(lactic-co-glycolic acid) (PLGA), copolymers of L-lactide and D,L-lactide, polyester copolymers, diblock copolymers consisting of MPEG and PCL, MPEG and PCL-ran-PLLA, MPEG and PLGA, PEO and PLLA, trimethylated chitosan and α,β-glycerophosphate, triblock copolymers consisting of PEO and PLLA, PLGA-PEG-PLGA, PEG-PLGA-PEG, PEG-PCL-PEG, and PEO-PPO-PEO (Poloxamers), wherein preferred hydrogel-based matrices are biodegradable or biostable polymers, more preferably biodegradable, even more preferably thermogelling, and most preferably reverse thermogelling, and wherein the gelling temperature is between 20°C and 40°C, preferably between 25°C and 35°C, and/or wherein more than 50% degradation of the polymer weight in body environment and/or more than 50% release of embedded tolerance-promoting adjuvants and/or tolerance-promoting immune modulators from the polymer is completed within 1 to 10 days, preferably within 1 to 5 days.
number: 3
text: Composition of claim 1, wherein matrix-embedded tolerance-promoting adjuvants are selected from poly(lactic-co-glycolic acid) micro- and nanoparticles (PLGA particles) and phosphatidyl-L-serine-containing liposomes (PS-liposomes), wherein preferred tolerance-promoting adjuvants contain one or more encapsulated low molecular find-me molecules for enhanced peripheral phagocytosis of said tolerance-promoting adjuvants, and wherein most preferred tolerance-promoting adjuvants allow the sustained release of encapsulated low molecular find-me molecules within a period of 2 to 5 days.
number: 4
text: Composition of claim 1, wherein low molecular find-me molecules for enhanced peripheral phagocytosis are selected from lysophosphatidylcholine (LPC), sphingosine-1-phosphate (S1P) and the nucleotides ATP and UTP, wherein preferred low molecular find-me molecules are ATP and/or UTP, wherein said low molecular find-me molecules are embedded in a matrix according to claim 2, preferably as PLGA-encapsulated or PS-liposome-encapsulated formulation.
number: 5
text: Composition of claim 1, wherein tolerance-promoting immune modulators include but are not limited to a) vitamin D3 and selected analogs such as calcipotriol, b) glucocorticoids such as dexamethasone phosphate, c) Janus kinase (JAK) inhibitors such as tofacitinib, d) antagonistic cytokine molecules such as Il-4/IL-13 muteins, e) salicylate-based therapeutics for the inhibition of TNFR1-mediated pathways, f) peptide- or peptidomimetic-based complement inhibitors, and g) aptamer-based inhibitors of pro-inflammatory cytokines, wherein preferred tolerance-promoting immune modulators are low to medium molecular weight immune modulators which provide a relatively short serum half-life that is sufficient to be locally active upon their release from a depot at the site of autoantigen or allergen presentation, and which allows fast removal from circulation upon diffusion and transport away from the site of autoantigen or allergen presentation.
number: 6
text: Composition of claim 1, wherein matrix-embedded allergens include allergen extracts, cross-linked allergen extracts (allergoids), depigmented allergoids, one or more purified natural allergens, one or more recombinant allergens or derivatives thereof, and one or more fragments of natural or recombinant allergens, wherein matrix-embedded autoantigens include one or more purified natural autoantigens, one or more recombinant autoantigens or derivatives thereof, and one or more fragments of natural or recombinant autoantigens.
number: 7
text: Composition according to any of the claims 1 to 6, wherein all components are mixed as a single preparation comprising the matrix according to claim 2, one or two therapeutically effective doses of tolerance-promoting adjuvants according to claim 3, one or more therapeutically effective doses of low molecular find-me molecules for enhanced peripheral phagocytosis according to claim 4, one or more therapeutically effective doses of tolerance-promoting immune modulators according to claim 5, and one or more therapeutically effective doses of allergen or autoantigen according to claim 6, wherein the composition is galenically prepared for administration by injection or by implantation, intradermally, subcutaneously, nasally, transbucally, transmucosally, sublingually, intraocularly, intramus-cularly, or topically.
number: 8
text: Composition according to claim 1, comprising matrix-embedded allergens or autoantigens or fragments thereof, wherein the tolerance-promoting adjuvant is PLGA-particles,
wherein the low molecular weight find-me molecule is ATP or UTP , and wherein the tolerance-promoting immune modulator is calcipotriol.
number: 9
text: Composition according to claim 1, comprising matrix-embedded allergens or autoantigens or fragments thereof, wherein the tolerance-promoting adjuvant is PLGA-particles, wherein the low molecular weight find-me molecule is ATP or UTP , and wherein the tolerance-promoting immune modulator is dexamethasone phosphate.
number: 10
text: Composition according to claim 1, comprising matrix-embedded allergens or autoantigens or fragments thereof, wherein the tolerance-promoting adjuvant is phosphatidyl-L-serine-containing liposomes (PS-liposomes),wherein the low molecular weight find-me molecule is ATP or UTP , and wherein the tolerance-promoting immune modulator is tofacitinib.
number: 11
text: Use of a composition according to one of the claims 1 to 10 for modulation of antigen-presenting cell, T cell and B cell responses by allergen- aor autoantigen-specific immunotherapy in a mammalian organism, preferably a human, in need thereof, in particular for the treatment of T cell-mediated diseases, preferably selected from the group consisting of allergy, allergic asthma, type 1 diabetes, rheumatoid arthritis, and multiple sclerosis, autoimmune uveitis and wherein the pharmaceutical composition is administered in a therapeutically effective dose.
number: 12
text: Methods for manufacturing a pharmaceutical composition according to one of the claims 1 to 10, wherein the components are mixed with each other in a therapeutically effective quantity, wherein optionally galenic compounds are additionally admixed to one or all of the preparations.
Office action: search_report, dated 2017-12-06
Rejection reasons: novelty_epc_54
inventive_step_epc_56
Prior art cited: ref_id: EP2918262A1
ref_type: patent
severity: background
ref_id: WO2013155487A1
ref_type: patent
severity: background
ref_id: WO2015171079A1
ref_type: patent
severity: background
ref_id: EP3095440A1
ref_type: patent
severity: background
ref_id: [XDY]     - DE SOUZA REBOUCAS JULIANA ET AL: "Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy", JOURNAL OF BIOMEDICINE & BIOTECHNOLOGY, 2012, XP055390880
ref_type: npl
severity: background
ref_id: - "Tofacitinib", DRUGS R D 2010; 10 (4), 1 January 2010 (2010-01-01), pages 271 - 284, XP055095587, Retrieved from the Internet <URL:http://download.springer.com/static/pdf/686/art%3A10.2165%2F11588080-000000000-00000.pdf?auth66=1389450185_3923eea48b6eee8434112362ba3070d0&ext=.pdf> [retrieved on 20140109]
ref_type: npl
severity: background
ref_id: WO2013155487
ref_type: patent
severity: novelty_destroying
ref_id: EP2918262
ref_type: patent
severity: novelty_destroying
ref_id: WO2015171079
ref_type: patent
severity: obviousness
ref_id: EP3095440
ref_type: patent
severity: novelty_destroying
ref_id: - DE SOUZA REBOUCAS JULIANA ET AL, "Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy", JOURNAL OF BIOMEDICINE & BIOTECHNOLOGY, (2012), XP055390880 [XD] 1,2 * Abstract, page 6 * [Y] 1-12
ref_type: npl
severity: novelty_destroying
ref_id: - "Tofacitinib", Drugs R D 2010; 10 (4), (20100101), pages 271 - 284, URL: http://download.springer.com/static/pdf/686/art%3A10.2165%2F11588080-000000000-00000.pdf?auth66=1389450185_3923eea48b6eee8434112362ba3070d0&ext=.pdf, (20140109), XP055095587 [Y] 10 * the whole document *
ref_type: npl
severity: obviousness
Final disposition: pending (2017-12-06)